Article

Kidney Cancer News and Updates That Patients May Have Missed in 2020

Author(s):

CURE staff

A roundup of some kidney cancer news and updates that occurred in 2020 that patients may have missed.

There were several updates in the field of kidney cancer in 2020. Here, CURE® looks back at some of the news and updates in the field that patients may have missed.

  • At five years of follow-up, treatment with Opdivo (nivolumab) demonstrated superior overall survival and objective response rates, compared with Afinitor (everolimus), in patients with previously treated advanced or metastatic renal cell carcinoma (RCC), according to results from the phase 3 Checkmate-025 study. READ MORE.
  • Patients with advanced, previously untreated RCC may soon have a new option in the novel combination of Opdivo (nivolumab) and Cabometyx (cabozantinib), according to phase 3 results of the CheckMate-9ER trial. READ MORE.
  • Birth weight, height and childhood body mass index (BMI) are associated with adult RCC, meaning they could be valuable predictors for a person’s risk of disease, according to new findings published in the European Journal of Epidemiology. READ MORE.
  • Data presented at the 2020 ASCO Virtual Scientific Program demonstrated that treatment with savolitinib showed encouraging efficacy and an improved safety data over standard-of-care Sutent (sunitinib) in patients with MET-driven papillary RCC. READ MORE.
  • Treatment with Cabometyx (cabozantinib) in combination with Tecentriq (atezolizumab) demonstrated promising clinical activity in patients with advanced clear cell RCC, according to data presented at the 2020 ESMO Virtual Congress. READ MORE.
  • Data from a phase 2 study presented during the 2020 ASCO Virtual Scientific Program demonstrated that Avastin (bevacizumab) in combination with Tarceva (erlotinib) was well tolerated and produced encouraging clinical outcomes in patients with advanced hereditary leiomyomatosis and RCC or sporadic papillary RCC. READ MORE.
  • Fotivda (tivozanib) significantly improved survival, compared with Nexavar (sorafenib), in patients with highly relapsed or refractory metastatic RCC, according to results from the phase 3 TIVO-3 trial presented at the 2020 ASCO Virtual Scientific Program. READ MORE.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Image of a man wearing a black suit and tie.
Image of a man with rectangular glasses and a goatee.
Image of a woman with a brown hair tied into a bun.
Man in a navy suit with a purple tie. Dr. Saby George talks to CURE about how treatment with Opdivo could mitigate disparities in patients with kidney cancer.
Tian Zhang, MD, MHS, an expert on renal cell carcinoma
Chandler H. Park, MD, an expert on renal cell carcinoma
Related Content
The combination of first-line Bavencio and Inlyta was effective and safe in advanced RCC; stock.adobe.com
February 20th 2025

Real-World Data Confirms Safety of Bavencio and Inlyta in Advanced RCC

Ashling Wahner
In a real-world analysis of patients with advanced RCC, the combination of first-line Bavencio and Inlyta was effective and safe.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Illustration of kidneys.
February 18th 2025

Cancer Vaccine Elicits Promising Responses in Renal Cell Carcinoma

Alex Biese
All nine patients treated with a personalized cancer vaccine following removal of their tumors remained cancer-free at a median data cut-off of 34.7 months.
cancer horizons podcast logo
December 20th 2023

FDA Approves 3 Treatments, Cancer Vaccine Shows Promise

Alex Biese Brielle Benyon
The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.
Opdivo plus Cometyx resulted in a benefit versus Sutent in the first-line of advanced renal cell carcinoma treatment. © stock.adobe.com
February 15th 2025

Opdivo Plus Cabometyx Safe, Effective in Advanced Renal Cell Carcinoma

Tim Cortese
Opdivo plus Cabometyx resulted in a significant progression and survival benefits compared with Sutent in the first-line treatment of patients with advanced renal cell carcinoma.
Results were consistent with research in advanced renal cell carcinoma treated with Cabometyx, Opdivo and Yervoy: © SciePro - stock.adobe.com.
February 15th 2025

Cabometyx Combo Maintains Progression-Free Survival Benefit in Advanced RCC

Ariana Pelosci
Final results were consistent with previously conducted research in patients with advanced renal cell carcinoma treated with Cabometyx, Opdivo and Yervoy.